Your browser doesn't support javascript.
loading
NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.
Román-Rodríguez, Francisco José; Ugalde, Laura; Álvarez, Lara; Díez, Begoña; Ramírez, María José; Risueño, Cristina; Cortón, Marta; Bogliolo, Massimo; Bernal, Sara; March, Francesca; Ayuso, Carmen; Hanenberg, Helmut; Sevilla, Julián; Rodríguez-Perales, Sandra; Torres-Ruiz, Raúl; Surrallés, Jordi; Bueren, Juan Antonio; Río, Paula.
Afiliação
  • Román-Rodríguez FJ; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Ugalde L; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Álvarez L; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Díez B; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Ramírez MJ; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Genome Instability and DNA Repair Syndromes Group, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), Barcelona 08193, Spain; Servicio de Genética e Instituto de Inves
  • Risueño C; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Cortón M; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Department of Genetics, Hospital Universitario Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid 28040, Spain.
  • Bogliolo M; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Genome Instability and DNA Repair Syndromes Group, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), Barcelona 08193, Spain; Servicio de Genética e Instituto de Inves
  • Bernal S; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Servicio de Genética e Instituto de Investigaciones Biomédicas del Hospital de Sant Pau, Barcelona 08025, Spain.
  • March F; Servicio de Genética e Instituto de Investigaciones Biomédicas del Hospital de Sant Pau, Barcelona 08025, Spain.
  • Ayuso C; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Department of Genetics, Hospital Universitario Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid 28040, Spain.
  • Hanenberg H; Department of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, Düsseldorf 40225, Germany; Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen 45122, Germany.
  • Sevilla J; Hospital Universitario Niño Jesús, Madrid 28009, Spain.
  • Rodríguez-Perales S; Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain.
  • Torres-Ruiz R; Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain; Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona 08036, Spain.
  • Surrallés J; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Genome Instability and DNA Repair Syndromes Group, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), Barcelona 08193, Spain; Servicio de Genética e Instituto de Inves
  • Bueren JA; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
  • Río P; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 28040, Spain; Advanced Therapies Unit, Instituto de Investigaci
Cell Stem Cell ; 25(5): 607-621.e7, 2019 11 07.
Article em En | MEDLINE | ID: mdl-31543367
ABSTRACT
Non-homologous end-joining (NHEJ) is the preferred mechanism used by hematopoietic stem cells (HSCs) to repair double-stranded DNA breaks and is particularly increased in cells deficient in the Fanconi anemia (FA) pathway. Here, we show feasible correction of compromised functional phenotypes in hematopoietic cells from multiple FA complementation groups, including FA-A, FA-C, FA-D1, and FA-D2. NHEJ-mediated repair of targeted CRISPR-Cas9-induced DNA breaks generated compensatory insertions and deletions that restore the coding frame of the mutated gene. NHEJ-mediated editing efficacy was initially verified in FA lymphoblastic cell lines and then in primary FA patient-derived CD34+ cells, which showed marked proliferative advantage and phenotypic correction both in vitro and after transplantation. Importantly, and in contrast to homologous directed repair, NHEJ efficiently targeted primitive human HSCs, indicating that NHEJ editing approaches may constitute a sound alternative for editing self-renewing human HSCs and consequently for treatment of FA and other monogenic diseases affecting the hematopoietic system.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / Transplante de Células-Tronco Hematopoéticas / Proteína do Grupo de Complementação A da Anemia de Fanconi / Anemia de Fanconi / Reparo do DNA por Junção de Extremidades / Sistemas CRISPR-Cas / Edição de Genes Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / Transplante de Células-Tronco Hematopoéticas / Proteína do Grupo de Complementação A da Anemia de Fanconi / Anemia de Fanconi / Reparo do DNA por Junção de Extremidades / Sistemas CRISPR-Cas / Edição de Genes Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article